CONTRAFECT CORPORATION ContraFect
Differentiated, first-in-class direct lytic agents (DLAs) for life-threatening,drug-resistant infections
August 2021
Forward Looking Statements
This presentation contains, and our officers and representatives may from time to time make, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believe," "expect," "target", "anticipate," "estimate," "intend," "plan," "proposed", "potential" or similar references to future periods. Examples of forward-looking statements in this presentation include, without limitation, statements made regarding ContraFect Corporation's ("ContraFect") ability to develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic- resistant infections, cited information, ContraFect's End-of Phase 2 meeting with the FDA, Phase 3 plans, designs and timing, Phase 2 study results, data analyses and comparisons, health economic data, safety and efficacy of exebacase, exebacase's value proposition, patent protection, commercial assessments, in vitro and in vivo study results, ContraFect's plans regarding its next IND and extrapolated data. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, proposals, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and other filings with the Securities and Exchange Commission ("SEC"). Actual results may differ from those set forth in the forward- looking statements. Important factors that could cause actual results to differ include, among others, the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect's product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection. Any forward-looking statement made by ContraFect in this presentation is based only on information currently available and speaks only as of the date on which it is made. No representation or warranty is made as to the completeness or accuracy of the information provided in this presentation. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward- looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Audiences are cautioned that forward-looking statements or similar information are not guarantees of future performance and, accordingly, are expressly cautioned not to put undue reliance on forward-looking statements or similar information due to the inherent uncertainty therein.
2 | ©2021 ContraFect Corporation |
ContraFect is a late clinical-stage biotechnology company leading the development of direct lytic agents (DLAs), which include lysins and amurin peptides, as new medical modalities for the treatment of life- threatening and antibiotic-resistant infections
ContraFect Leadership
Executive Management
Roger Pomerantz, MD, FACP - CEO | Cara Cassino, MD, FCCP - CMO & EVP, R&D | ||||
Natalie Bogdanos - GC, Secretary & DPO
Board of Directors
Roger Pomerantz, MD, FACP - Chair | Lishan Aklog, MD | ||||||||
Former Chairman and CEO of Seres | |||||||||
CEO, PAVmed | |||||||||
Sol Barer, PhD - Lead Independent | Jane F. Barlow, MD, MPH | ||||||||
Former Chairman and CEO of Celgene | |||||||||
EVP & CCO, Real Endpoints | |||||||||
Steven C. Gilman, PhD - Vice Chair | Former Associate CMO, CVS Health | ||||||||
Former CEO, ContraFect | Former VP, Clinical Innovation, Medco | ||||||||
Former EVP, R&D and CSO, Cubist | |||||||||
4 |
Michael Messinger - CFO
David Low
Investment Banker at MTS
Formerly at Lazard, JP Morgan, Lehman
Michael Otto, PhD
Former CSO, Pharmasset
Cary Sucoff
President, Equity Source Partners
©2021 ContraFect Corporation
21st Century Medical Paradigm Shifts in Standard-of-Care
Prior Treatment | New Standard-of-Care | |||||
Antibiotics | Superiority | Microbiome | ||||
Mortality benefits | ||||||
Anti-Infectives | Direct lytic | |||||
Positive health | ||||||
agents | ||||||
economics | ||||||
Chemotherapy | ||||||
Cancer | Immunotherapies | |||||
Congenital | No treatments | Gene therapies |
Disorders | available | |
5 | ©2021 ContraFect Corporation |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
ContraFect Corporation published this content on 23 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 August 2021 13:14:14 UTC.
